background: Clomiphene citrate (CC) is the first-line therapy for the induction of ovulation in infertile women with polycystic ovary syndrome (PCOS), but 20% of patients are unresponsive. The aim of the current study was to test the hypothesis that a 6-week intervention that consisted of structured exercise training (SET) and hypocaloric diet increases the probability of ovulation after CC in overweight and obese CC-resistant PCOS patients.
Introduction
Clomiphene citrate (CC) was the first agent used to induce ovulation in oligomenorrheic women, and it is still considered the first therapeutic option for the management of anovulatory infertility related to polycystic ovary syndrome (PCOS; Palomba et al., 2004) . In fact, a recent meta-analysis (Brown et al., 2009) has demonstrated that CC increases the pregnancy rate by .6-fold in comparison with placebo or no treatment.
At present, the United Kingdom National Institute for Clinical Excellence (NICE, 2004) and World Health Organization (WHO, 2002) guidelines state that first-line treatment for anovulatory patients should be CC for up to 12 months. Similarly, the European Society of Human Reproduction and Embryology (ESHRE) and the American Society for Reproductive Medicine (ASRM) recommend induction of ovulation with CC for up to six ovulatory cycles as the first-line drug treatment for PCOS-related infertility (The Thessaloniki ESHRE/ASRMSponsored PCOS Consensus Workshop Group, 2008) .
Notwithstanding the efficacy of CC, ovulation is not achieved in a proportion of patients, although a maximum dosage is used. These patients are defined generally as CC-resistant (Kousta et al., 1997) . Traditionally, CC is administered up to a maximum dose of 250 mg daily to obtain an optimal clinical response (Gysler et al., 1982) . However, in more than 75% of cases, ovulation occurs with a dose of 150 mg/day, and increasing the dose confers no significant reproductive benefits in terms of ovulation (Imani et al., 1998 (Imani et al., , 1999 but only peripheral adverse effects (Palomba et al., 2006a,b) . Therefore, 150 mg/day CC is considered the highest dose that should be administered (NICE, 2004) . In this regard, the United States (US) Food and Drug Administration (FDA) has suggested that doses of CC should not exceed 750 mg per cycle (Dickey and Holtkamp, 1996) .
CC resistance represents an important clinical problem that affects up to 25% of infertile women with PCOS. In these patients, several combined or alternative treatments have been proposed for inducing ovulation (Palomba et al., 2009) . Second-line strategies to induce ovulation in CC-resistant PCOS patients are based on treatments with mechanisms of action that are different from those of CC, such as aromatase inhibitors, or treatments that sensitize the ovary to subsequent or concomitant administration of CC, such as ovarian drilling and metformin (Palomba et al., 2009) . The re-administration of CC using luteal-phase CC treatment and a stair-step CC protocol has been also proposed (Palomba et al., 2009) .
To date, the administration of metformin in parallel with CC is probably the most common second-line treatment for PCOS-related anovulation. Metformin seems to sensitize the ovary to CC via mechanisms that are probably related to its insulin-sensitizing action, when it is administered in pretreatment protocols (Palomba et al., 2009) .
Lifestyle modification programmes are considered unanimously to be a valid alternative to drug therapy for obese women with anovulatory infertility (Cussons et al., 2005; Pasquali et al., 2006; Palomba et al., 2008) , and many clinicians and recent guidelines regard lifestyle management as the primary therapy in overweight and obese women with PCOS (The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2008; Moran et al., 2009) . Surprisingly, no data are available in the literature regarding the specific clinical efficacy of physical exercise and/or diet in CC-resistant PCOS.
The aim of the present study was to test the hypothesis that a 6-week intervention that consisted of structured exercise training (SET) and a hypocaloric diet could increase the ovulation rate after CC administration in PCOS patients with known CC resistance.
Materials and Methods
The procedures used during the study were in accordance with the principles laid down by the Declaration of Helsinki on human experimentation and good clinical practice. The study protocol was approved by the Ethical Committee of the Department of Gynecology & Obstetrics (University 'Magna Graecia', Catanzaro, Italy). The purpose of the protocol was explained carefully and detailed information was given to each patient about the role of weight loss in reproductive disorders and the benefits of lifestyle modification, with particular regard to physical activity and diet. Written informed consent was obtained from each patient.
Population
From February 2008 to August 2009, 96 overweight and/or obese PCOS patients with anovulatory infertility and known CC resistance were enrolled in a randomized, parallel, controlled assessor-blinded clinical trial (registration number NCT01004068 at www.clinicaltrial.gov).
Diagnosis of PCOS was based on the presence of chronic anovulation, confirmed by serum progesterone (P) levels ,2 ng/ml randomly assessed for at least the two consecutive months prior to the study start, and of clinical and/or biochemical hyperandrogenism [Ferriman-Gallwey score ≥8 (Ferriman and Gallwey, 1961) and elevated serum androstenedione and/or dehydroepiandrosterone sulphate (DHEA-S) and/or total testosterone concentrations according to normal reference values].
The diagnosis of anovulatory infertility was made on the basis of regular sexual intercourse for at least 1 year and a history of irregular periods (cycle length .35 days), as well as normal serum FSH and estradiol (E 2 ) levels (The ESHRE Capri Workshop Group, 1995) .
Patients were defined as CC-resistant if they had failed to ovulate after treatment under an incremental regimen with a maximum dose of 150 mg CC/day. Under this regimen, CC was administered for 5 days beginning at Day 3 following a P-induced withdrawal bleeding with a starting dose of 50 mg daily. If ovulation did not occur, this dose was increased by increments of 50 mg in successive cycles, until ovulation was achieved or a maximal dose of 150 mg daily was reached.
Subjects were considered to be overweight or obese if their body mass index (BMI) was 25 -30 or .30, respectively (National Heart, Lung, and Blood Institute/National Institutes of Diabetes and Digestive and Kidney Diseases, 1998).
The exclusion criteria included: age ,18 or .35 years; BMI , 25 and ≥35; major medical disorders or other concurrent medical illnesses; and current or previous use of hormonal, anti-diabetic or anti-obesity drugs, or other drugs that affect hormone levels, carbohydrate metabolism or appetite.
Protocol and interventions
After careful selection according to the above inclusion and exclusion criteria, all eligible subjects were enrolled and randomly allocated into three treatment arms of 32 women each (Groups A, B and C). The study was single blind, i.e. assessors were masked to the treatment assignment, whereas those giving the interventions and the enrolled patients were aware of the assigned treatment because the interventions differed. The random allocation sequence was made in single blocks, i.e. by using a single sequence of random and obtained with the use of a computergenerated randomization list. The sequence was concealed from all investigators until the interventions were assigned using sequentially numbered opaque sealed envelopes that were prepared distant from the study site.
At the start of the study, 100 mg natural P was administered to each woman intramuscularly.
During the first 2 weeks, Groups A and C underwent SET and were given a hypocaloric diet, whereas Group B underwent observation alone. During the following 4 weeks, Groups A and C continued with SET and the hypocaloric diet, and Groups B and C received one cycle of CC therapy.
The interventions and the timing of follow-ups for each arm are summarized in Fig. 1 .
The SET consisted of three training sessions per week, during which the subjects exercised for 30 min on a bicycle ergometer and the exercise workload was increased gradually until a target of 60 -70% of maximal oxygen consumption was achieved, according to an initial cardiopulmonary exercise test (Vigorito et al., 2007; Palomba et al., 2008) . Each session was preceded by a 5-min warm-up and followed by a 5-min cool down. The training sessions were performed under continuous electrocardiographic monitoring and supervised by a cardiologist.
The hypocaloric diet was characterized by a high protein composition (35% protein, 45% carbohydrate and 20% fat), and energy inputs were adjusted to create a 1000-kcal deficit per day on the basis of the normal daily caloric input previously calculated for each patient.
After a 2-week period of observation (Group B) or SET and hypocaloric diet (Group C), and in the absence of any ovarian response at ultrasound evaluation, CC was given at a fixed dose of 150 mg/day for 5 days. In the case of follicular development, no agent to induce ovulation was administered, patients carried on with their original treatment, and were excluded from the final analysis.
At entry into the study and at 2 weeks follow-up, clinical, biochemical and ultrasonographic assessments were performed. At the end of the study, anthropometric data were evaluated, and reproductive outcomes were noted as described below. In addition, compliance to the interventions was evaluated in all cases.
Ovulation was monitored by serial transvaginal ultrasonographic scans performed by the same experienced operator (T.R.) at baseline, every 4 days, and successively daily until ovulation in case of a dominant follicle with a mean diameter of ≥12 mm. Ovulation was identified retrospectively by observation of a decrease in follicular dimensions and liquid in the cul-de-sac, and was confirmed by plasma P assay (.10 ng/ml) assessed 7 days before the expected menses on the basis of ultrasonographic findings.
In the absence of menstrual bleeding, a pregnancy test was performed in all patients in whom ovulation had occurred. If pregnancy was achieved, patients stopped the assigned treatments, i.e. SET and hypocaloric diet or CC, and were followed in our institution; otherwise, withdrawal bleeding was induced by medroxyprogesterone acetate (10 mg/day for 10 days).
To evaluate adherence to the SET intervention, the number of SET sessions missed per week was recorded. We considered no sessions missed per week as 'high adherence', one session missed per week as 'moderate adherence', and more than one session missed per week as 'low adherence'. The lack of adherence to the dietary programme was defined as the inability to tolerate the caloric restriction or composition of the diet, and was calculated according to the degree of change with respect to caloric intake and dietary composition. In particular, adherence was defined as 'high' with a mean caloric deficit .4900 kcal/week and/ or with a dietary composition of 30 -35% protein and 45 -50% carbohydrate; 'moderate' with a mean caloric deficit of 3500 -4900 kcal/ week and/or with a dietary composition of 25 -30% protein and 50 -55% carbohydrate; and 'low' with a mean caloric deficit ,3500 kcal/ week and/or with a dietary composition of ,25% protein and .55% carbohydrate.
Interactive group educational meetings were organized to improve the adherence rate. Conversely, in order to eliminate bias due to arbitrary changes in diet and physical activity, daily diet and physical activity were monitored in all patients using two well-validated questionnaires (Roeykens et al., 1998; Willett, 1998) . In particular, daily dietary monitoring consisted of compiling personal charts and sending them weekly to the investigators, and food consumption was assessed using a selfadministered, semi-quantitative, well-validated food-frequency questionnaire (Willett, 1998) , which was used to cross-check the dietary history. Daily diet was evaluated with the aid of software that is specific for the analysis of food habits and for the estimation of nutrient and caloric intake (WinFood version 1.5; Medimatica, Martinsicuro, Italy). The monitoring of daily physical activity consisted of a leisure-time physical activity (LTPA) questionnaire and calculation of a weekly energy expenditure score (total LTPA level) in metabolic equivalents per hour/week, by using a standardized classification of the energy expenditure associated with particular physical activities (Ainsworth et al., 2000) . Lifestyle modifications and CC-resistance
Clinical and biochemical assessments
Clinical evaluation consisted of calculation of the Ferriman-Gallwey score (Ferriman and Gallwey, 1961) and anthropometric measurements, which included height, body weight (BW), BMI, waist circumference (WC) and waist-to-hip ratio (WHR).
At baseline and 2 weeks after the start of the study, and after sonographic evaluation confirmed ovarian quiescence, a venous blood sample was taken from each participant between 08:00 and 09:00 h after fasting for 12 h and resting in bed to assess the complete hormonal profile and fasting glucose and insulin levels. The complete hormonal profile included the evaluation of levels of FSH, LH, thyroid-stimulating hormone (TSH), prolactin (PRL), E 2 , P, 17-OH-progesterone (17-OHP), testosterone, androstenedione, DHEAS and sex-hormone-binding globulin (SHBG). In each participant, homeostasis model of assessment of insulin resistance (HOMA-IR), fasting glucose-to-insulin ratio (GIR) (mg/10 24 U) and free androgen index (FAI) were calculated. Each participant was instructed to record in a personal daily diary the onset of any adverse effects, together with their severity, duration and any possible cause -effect relationship with the interventions, and the quantity of menstrual bleeding, which was evaluated subjectively by using a rank analogue scale that ranged from 0 (absence of menses) to 5 (normal uterine bleeding) and 10 (severe uterine bleeding).
Statistical analysis
The primary end-point of the study was the ovulation rate, defined as the number of women who ovulated divided by the total number of women studied. Secondary end points were other reproductive outcomes, changes in anthropometric, hormonal and metabolic parameters, as well as compliance with the interventions.
On the basis of previous data (Branigan and Estes, 2003) , re-administration of CC in resistant PCOS patients is associated with an ovulation rate of 10%. To detect an increase of 30% in the ovulation rate, which was defined as clinically significant, with 80% power and a twosided type I error of 5%, we calculated that 31 subjects were required for each group. To allow for an unpredictable number of withdrawals, we decided to enrol a total of 96 patients in the expectation that at least 31 would remain in each group.
Data were analysed by using the per-protocol and intention-to-treat (ITT) analyses on the basis of treatment receipt and assignment, respectively.
The Kolmogorov-Smirnov test with a Lilliefors significance level was used to test normality. Our data were normally distributed and expressed as mean + standard deviation (SD). Continuous variables were analysed by one-way analysis of variance (ANOVA), and ANOVA for repeated measures with the Bonferroni correction for the post hoc analysis. Differences in dichotomous outcomes among the three study groups were analysed with the use of the x 2 test or Fisher's exact test when the expected cell frequencies fell below five. The relative risk (RR) with 95% confidence interval (CI) for estimated ovulation and menstrual rates was calculated.
A P ≤ 0.05 was considered as statistically significant. SPSS version 13.0 (Chicago, IL, USA) was used for the statistical analyses. The power analysis and the sample size calculation were performed using SamplePower version 2.0.
Results
The flow-diagram of the clinical trial according to the consolidated CONSORT guidelines (Moher et al., 2001 ) is shown in Fig. 2 . No randomized subject was excluded from the final analysis, thus the data analysed according to the per-protocol analysis were the same as those analysed by the ITT analysis. In all cases, diagnosis of PCOS satisfied both the ESHRE/ASRM (Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2004) and the US National Institute of Health (Zawadski and Dunaif, 1992) criteria. At enrolment, all patients had polycystic ovaries at transvaginal ultrasonography (Balen et al., 2003) . At the start of the study, in all subjects, injection of P induced withdrawal uterine bleeding. 
Clinical and biochemical outcomes
The main clinical and biochemical data for the three groups at enrolment and after 2 weeks of follow-up are shown in Tables I and II, respectively . At entry into the study, no difference was detected among the three groups for any clinical or biochemical characteristics (Tables I and II) . The proportions of overweight and obese subjects did not differ between the groups (Table I ). Four subjects from Group A and three each from Groups B and C had glucose intolerance.
Two weeks after the study started, WC, testosterone, androstenedione, DHEAS and FAI were reduced significantly (P , 0.05) in Groups A and C compared with baseline, and there were no differences between these two groups (Tables I and II) . Both WC and FAI were significantly (P , 0.05) lower in Groups A and C when compared with Group B (Tables I and II) . At the same time, in Groups A and C, SHBG and GIR were significantly (P , 0.05) higher, and fasting insulin levels and HOMA-IR were significantly (P , 0.05) lower relative to Group B or their respective baselines (Table II) . There were no differences between Groups A and C.
Anthropometric data obtained at the end of the study are shown in Table I . At 6 weeks after the start of the study, BMI, BW, WC and WHR were reduced significantly (P , 0.05) in Groups A and C when compared with baseline and Group B, although there were no differences between Groups A and C (Table I) .
Reproductive outcomes
At 2 weeks after the start of the study, no ovarian response was detected in any of the patients in Group A, B or C. Therefore, no patients were excluded after randomization, and all patients continued with their assigned protocol.
After intervention, the ovulation rate was significantly (P ¼ 0.008) higher in Group C [12/32 (37.5%)] than in Groups A [4/32 (12.5%)] and B [3/32 (9.4%)] with a RR of 3.9 (95% CI 1.1-8.3; P ¼ 0.035) and 4.0 (95% CI 1.2-12.8; P ¼ 0.020) for Group C versus group A and B, respectively.
Only one patient from Group C became pregnant. The development of multiple follicles was observed in five patients; specifically, in two patients from Group B and in three from Group C. In all five cases, two follicles were observed, and the subjects were overweight rather than obese.
No statistically significant (P ¼ 0.262) difference in serum P levels (ng/ml) was detected among ovulatory patients from Groups A, B and C (15. Lifestyle modifications and CC-resistance end of the study, menstrual bleeding was observed in 4 patients in Group A (12.5%), 3 in Group B (9.4%) and 11 in Group C (34.4%) (P ¼ 0.012) with a RR of 2.8 (95% CI 1.0 -7.7; P ¼ 0.055) and 3.4 (95% CI 1.1-11.9; P ¼ 0.031) for Group C versus group A and group B, respectively. In addition, there were no differences in menstrual quantity among the three groups (data not shown).
Treatment compliance
Patients in groups A and C showed a similar adherence to the SET and dietary interventions (P ¼ 0.432). Specifically, no difference between Groups A and C was detected with respect to those showing high adherence [26/32 (81.3%) versus 25/32 (78.1%), respectively], moderate adherence [4/32 (12.5%) versus 5/32 (15.6 %), respectively] and low adherence [2/32 (6.3%) versus 2/32 (6.3%), respectively] to SET. None of the patients in Group A or C showed a lack of adherence to the dietary programme. No relevant adverse effect was observed throughout the study in any of the groups, and none of the patients dropped out. Data regarding LTPA levels throughout the study are depicted in groups at baseline. LTPA levels were improved significantly (P , 0.05) at 2 weeks after the start of the study and at the end of the study in Groups A and C, and there was no difference between these two groups. The LTPA level remained unchanged in Group B.
Discussion
The main finding of the present randomized controlled study was that a short-term lifestyle modification programme of 6 weeks had reproductive benefits in overweight and obese patients with PCOS who were resistant to CC. In particular, 2 weeks of SET and a hypocaloric diet improved ovarian response to CC, with an ovulation rate of 37.5% and a restoration of menstrual cycle in 34.4% of patients who were previously anovulatory after administration of a maximal dose of CC, and with RRs of about 4.0 and 3.4 for ovulation and menstrual cycle restoration, respectively. In addition, relevant differences in the ovulation rate were observed between patients who underwent SET plus a hypocaloric diet for 6 weeks plus one-cycle of CC administration and those who underwent either SET plus hypocaloric diet or one-cycle of CC administration alone (35.7% versus 12.5% or 9.4%). Several factors have been hypothesized to be involved in the clinical efficacy of the lifestyle interventions (Moran et al., 2007a,b; Thomson et al., 2009) . In a previous study, we attempted to characterize the mechanisms that underlie the efficacy of SET and diet in the restoration of ovarian function (Palomba et al., 2008) . Both interventions induced improvements in BW, BMI, WHR, WC, insulin resistance index, FAI, and serum testosterone and SHBG levels within 12 weeks, with no further changes over a longer period. Furthermore, the improvement in insulin sensitivity was hypothesized to be the pivotal factor involved in the restoration of ovarian function after SET and the dietary programme, even if this improvement was potentially related to loss of BW.
In the present study, we evaluated the main clinical and biochemical data at baseline and after 2 weeks of intervention to elucidate potential mechanisms of ovarian sensitization to CC due to SET and a hypocaloric diet. Although the follow-up was only short-term, we observed a reduction in hyperandrogenaemia and FAI, and an improvement in serum SHBG and insulin levels, GIR and HOMA-IR.
Previous studies have suggested that weight loss, even though minimal, could be the main factor involved in the restoration of fertility (Clark et al., 1995 (Clark et al., , 1998 Huber-Buchholz et al., 1999; Norman et al., 2004; Pasquali et al., 2006; Ramlau-Hansen et al., 2007; Palomba et al., 2008) . However, in the current study, there had been no significant reduction in BW at the point when CC was administered, which suggests that the increase in ovulatory response after CC treatment was unrelated to weight loss, which was only significant at the end of the study. In contrast, 2 weeks of SET and a hypocaloric diet resulted in a significant improvement in WC, which suggests a potential role of visceral fat reduction in enhancing ovulation. Visceral fat could change acutely in response to lifestyle modification, and reduce androgens and insulin resistance independently of BW. In the current study, SET and the hypocaloric diet alone restored ovarian function in 12.5% of anovulatory CC-resistant PCOS patients.
These lifestyle interventions have additional benefits at short-term follow-up. In fact, there is unanimous agreement on the advantages related to improved insulin sensitivity with respect to pregnancy and long-term risks, particularly in PCOS patients (Hoffman and Ehrmann, 2008) .
The main limitations of lifestyle intervention programmes are the lack of persistence with major lifestyle changes (Anderson et al., 2001) , and the high rate of dropout of 23-35% (Clark et al., 1995 (Clark et al., , 1998 Stamets et al., 2004; Palomba et al., 2008) . In the present study, the high rate of adherence to the dietary and SET programmes, with no dropouts, was probably due to sample characteristics and the protocol design. Our infertile patients had a high level of motivation because they were all overweight or obese and had not been responsive previously to CC administration. The interventions adopted were of short duration and easy to follow. In this regard, SET can be performed safely in healthy young subjects without any specific monitoring and specialist supervision even though they were part of the research protocol in our study.
An important point of discussion regards the economic aspects of a non-pharmacologic approach to CC resistance. In fact, a therapeutic intervention that consists of SET and a dietary programme should be considered as a valid and cheap option for CC-resistant PCOS patients in sites where a SET programme is already in use, mainly given the high direct and indirect costs of second-line treatments for infertility. On the basis of reports from the Italian Diagnosis Related Groups, the mean overall cost for each SET session in well-equipped centres is E250. Furthermore, in clinical practice, after a first daily ambulatory phase, these patients could be scheduled for home-based exercise programmes and dietary protocols.
The current randomized study has two main limitations. Firstly, it is lacking a placebo group for controlling the CC treated patients. Furthermore, our study protocol was designed for testing the hypothesis that a 6-week intervention consisting of SET and hypocaloric diet could increases the ovulation rate due to CC administration in CC-resistant PCOS patients. Therefore, all efforts were made for controlling the experimental intervention, whereas CC-treated groups were baseline-controlled. In addition, a placebo treatment would be accepted only with difficulty by infertile patients who desire a pregnancy as soon as possible. Secondly, the outcome measure studied, i.e. rate of ovulation, is not a robust end-point (Legro and Myers, 2004) for reproduction especially with a study design of only one cycle assessment. Therefore, even if just the short-term observation is peculiar and of clinical relevance, the present data should be considered preliminary.
In conclusion, in overweight and obese PCOS patients who are resistant to CC, a 6-week intervention of SET plus hypocaloric diet is an effective strategy to increase the probability of ovulation under CC after only one cycle of therapy. Further studies with live birth or baby-in-arm as the primary end-point are needed to confirm these encouraging preliminary findings at short-term follow-up and to make them clinically relevant.
